Mizuho Maintains Outperform on Kura Oncology, Lowers Price Target to $25

Benzinga Newsdesk www.benzinga.com Negative 92.5%

Neg 92.5% Neu 0% Pos 0%

Mizuho analyst Mara Goldstein maintains Kura Oncology (NASDAQ:KURA) with a Outperform and lowers the price target from $30 to $25.